| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Pentosan Polysulfate Sodium [PPS] |
| Brand | Elmiron® |
| Indication | For the treatment of bladder pain syndrome (BPS) characterized by either glomerulations or Hunner’s lesions in adults with moderate to severe pain, urgency and frequency of micturition. |
| Assessment Process | |
| Rapid review commissioned | 07/12/2018 |
| Rapid review completed | 24/01/2019 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that PPS not be considered for reimbursement at the submitted price. |
This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.
